Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · see citing works

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209 · see citing works

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · see citing works

Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans

Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 916 · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

Deacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · see citing works

International Textbook of Diabetes Mellitus

(2003) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 743 · see citing works

Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · see citing works

Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut

Holst, J. J., Ørskov, C., Nielsen, O. V., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · see citing works

Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1

Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595 · see citing works

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521 · see citing works

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · see citing works

Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice

Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454 · see citing works

Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion*

Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/endo.140.4.6643 · Cited by 452 · see citing works

Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms

I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · see citing works

Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78–107) amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach

Ørskov, C., Holst, J. J., & Nielsen, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 400 · see citing works

Attenuated GLP-1 secretion in obesity: cause or consequence

Ranganath, L. R., Beety, J. M., Morgan, L. M., Wright, J. W., Howland, R., & Marks, V (1996) · Gut · doi:10.1136/gut.38.6.916 · Cited by 394 · see citing works

Vagal, Cholinergic Regulation of Pancreatic Polypeptide Secretion

Schwartz, T. W., Holst, J. J., Fahrenkrug, J., Jensen, S. L., Nielsen, O. V., Rehfeld, J. F., de Muckadell, O. B. S., & STADIL, F. (1978) · Journal of Clinical Investigation · doi:10.1172/jci108992 · Cited by 386 · see citing works

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

Ørskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378 · see citing works

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · see citing works

A microfluorometric method for the determination of free fatty acids in plasma

Miles, J., Glasscock, R., Aikens, J., Gerich, J. E., & Haymond, M. W. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38029-9 · Cited by 329 · see citing works

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects

Elahi, D., McAloon-Dyke, M., Fukagawa, N. K., Meneilly, G. S., Sclater, A. L., Minaker, K. L., Habener, J. F., & Andersen, D. K. (1994) · Regulatory Peptides · doi:10.1016/0167-0115(94)90136-8 · Cited by 308 · see citing works

Influence of gender and menopause on gastric emptying and motility

Hutson, W. R., Roehrkasse, R. L., & Wald, A. M. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90758-0 · Cited by 304 · see citing works

Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects.

Bloom, S. R., Till, S. J., Sonksen, P., & Smith, S. (1984) · BMJ · doi:10.1136/bmj.288.6433.1793 · Cited by 278 · see citing works

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop.

Roberge, J. N., & Brubaker, P. L. (1993) · Endocrinology · doi:10.1210/endo.133.1.8319572 · Cited by 266 · see citing works

Detection of GAD65 Antibodies in Diabetes and Other Autoimmune Diseases Using a Simple Radioligand Assay

Petersen, J. S., Hejnæs, K. R., Moody, A. J., Karlsen, A. E., Marshall, M. O., Høier‐Madsen, M., Boel, E., Michelsen, B. K., & Dyrberg, T. (1994) · Diabetes · doi:10.2337/diab.43.3.459 · Cited by 264 · see citing works

Autonomic neuropathy: its diagnosis and prognosis

Ewing, D. J., & Clarke, B. F. (1986) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(86)80078-0 · Cited by 256 · see citing works

Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1

Nakabayashi, H., NISHIZAWA, M., Nakagawa, A., Takeda, R., & Niijima, A. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e808 · Cited by 203 · see citing works

Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms

Balkan, B., & Li, X. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.279.4.r1449 · Cited by 201 · see citing works

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

Hvidberg, A., Nielsen, M.-B., Hilsted, J., Ørskov, C., & Holst, J. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90164-3 · Cited by 195 · see citing works

Glucagon-like Peptide 1 (7-36 hide) Secretion in Response to Luminal Sucrose from the Upper and Lower Gut: A Study Using α-Glucosidase Inhibition (Acarbose)

Qualmann, C., Nauck, M. A., Holst, J. J., øSrskov, C., & Creutzfeldt, W. (1995) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529509101597 · Cited by 170 · see citing works

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.

Pederson, R. A., Satkunarajah, M., McIntosh, C. H. S., Scrocchi, L. A., Flamez, D., Schuit, F. C., Drucker, D. J., & Wheeler, M. B. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1046 · Cited by 167 · see citing works

Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene.

Cordier–Bussat, M., Bernard, C., Levenez, F., Klages, N., Ritz-Laser, B., Philippé, J., Chayvialle, J. A., & Cuber, J.-C. (1998) · Diabetes · doi:10.2337/diabetes.47.7.1038 · Cited by 164 · see citing works

Gastric and Oesophageal Emptying in Obesity

Maddox, A. F., Horowitz, M., Wishart, J., et al. (1989) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528909093095 · Cited by 158 · see citing works

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins

Vaag, A. A., Holst, J. J., Vølund, A., & Beck‐Nielsen, H. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350425 · Cited by 154 · see citing works

Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy

Miholic, J., �rskov, C., Holst, J. J., Kotzerke, J., & Meyer, H.-J. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01296800 · Cited by 154 · see citing works

Diminished Immunoreactive Gastric Inhibitory Polypeptide Response to a Meal in Newly Diagnosed Type I (Insulin-Dependent) Diabetics*

Krarup, T., Madsbad, S., Moody, A. J., Regeur, L., FABER, O. K., Holst, J. J., & Sestoft, L. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1306 · Cited by 150 · see citing works

Gastrointestinal function in obesity: Motility, secretion, and absorption following a liquid test meal

Wisén, O., & Johansson, C. (1992) · Metabolism · doi:10.1016/0026-0495(92)90073-j · Cited by 119 · see citing works

Distal Small Bowel Hormones (Correlation with Fasting Antroduodenal Motility and Gastric Emptying)

Näslund, E. B., Grybäck, P., Bäckman, L., Jacobsson, H., Juul, J. J., Theodorsson, H. E., & Hellström, P. M. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018806129102 · Cited by 116 · see citing works

Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

Larsson, H. E., Holst, J. J., & Åhrén, B. (1997) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1997.00161.x · Cited by 115 · see citing works

Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine

Hansen, L. (1999) · Endocrinology · doi:10.1210/en.140.11.5356 · Cited by 112 · see citing works

The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera

Krarup, T., & Holst, J. J. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90005-3 · Cited by 110 · see citing works

Immunoreactive Gastric Inhibitory Polypeptide*

Krarup, T. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-1-122 · Cited by 94 · see citing works

Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion

Rocca, A. S. (1999) · Endocrinology · doi:10.1210/en.140.4.1687 · Cited by 91 · see citing works

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop

Roberge, J. N. (1993) · Endocrinology · doi:10.1210/en.133.1.233 · Cited by 88 · see citing works

Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay

Petersen, J. S., Hejnæs, K. R., Moody, A., et al. (1994) · Diabetes · doi:10.2337/diabetes.43.3.459 · Cited by 83 · see citing works

Gastric emptying in diabetes mellitus: relationship to blood-glucose control

Kong, M.-F., & Horowitz, M. (1999) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30062-4 · Cited by 80 · see citing works

Hypersecretion of Truncated Glucagon‐like Peptide‐1 and Gastric Inhibitory Polypeptide in Obese Patients

Fukase, N., Igarashi, M., Takahashi, H., Manaka, H., Yamatani, K., Daimon, M., Tominaga, M., & Sasaki, H. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb01995.x · Cited by 69 · see citing works

Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance

Ahrén, B., Larsson, H. E., & Holst, J. J. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370127 · Cited by 54 · see citing works

Inhibition of carbohydrate-mediated glucagon-like peptide-I (7–36)amide secretion by circulating non-esterified fatty acids

RANGANATH, L., NORRIS, F., MORGAN, L., WRIGHT, J., & MARKS, V. (1999) · Clinical Science · doi:10.1042/cs0960335 · Cited by 47 · see citing works

Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus

Fukase, N., Manaka, H., Sugiyama, K., Takahashi, H., Igarashi, M., Daimon, M., Yamatani, K., Tominaga, M., & Sasaki, H. (1995) · Acta Diabetologica · doi:10.1007/bf00838486 · Cited by 36 · see citing works

Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7‒36)amide secretion by circulating non-esterified fatty acids

Ranganath, L. R., Norris, F., Morgan, L., WRIGHT, J., & Marks, V. (1999) · Clinical Science · doi:10.1042/cs19980308 · Cited by 20 · see citing works

Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients

Fukase, N., Takahashi, H., Igarashi, M., et al. (1992) · Regulatory Peptides · doi:10.1016/0167-0115(92)90217-i · Cited by 4 · see citing works

The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.

DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016 · see citing works

Pancreatic regulation of glucose homeostasis.

Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985 · see citing works

Incretin hormones: Their role in health and disease

Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950 · see citing works

The role of incretins in glucose homeostasis and diabetes treatment

Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824 · see citing works

Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes

Laferrère, B., Teixeira, J., McGinty, J., Tran, H., Egger, J. R., Colarusso, A., Kovack, B., Bawa, B., Koshy, N., Lee, H., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2851 · Cited by 682 · see citing works

Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans

Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611 · see citing works

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes

Laferrère, B., Heshka, S., Wang, K., Khan, Y., McGinty, J., Teixeira, J., Hart, A. B., & Olivan, B. (2007) · Diabetes Care · doi:10.2337/dc06-1549 · Cited by 532 · see citing works

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · see citing works

The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology, and response to therapeutic interventions

Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503 · see citing works

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465 · see citing works

Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403 · see citing works

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414 · see citing works

Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients

Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · see citing works

The evolving story of incretins ( <scp>GIP</scp> and <scp>GLP</scp> ‐1) in metabolic and cardiovascular disease: A pathophysiological update

Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388 · see citing works

The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369 · see citing works

A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365 · see citing works

Reduced Incretin Effect in Type 2 Diabetes

Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349 · see citing works

GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study

Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321 · see citing works

Prediabetes and Cardiovascular Disease

Brannick, B., & Dagogo-Jack, S. (2018) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.001 · Cited by 293 · see citing works

Glucagon-like peptide 1(GLP-1) in biology and pathology

Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288 · see citing works

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010) · Diabetes · doi:10.2337/db09-1414 · Cited by 276 · see citing works

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251 · see citing works

Preservation of β-Cell Function: The Key to Diabetes Prevention

DeFronzo, R. A., & Abdul-Ghani, M. A. (2011) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2011-0246 · Cited by 247 · see citing works

Impaired regulation of the incretin effect in patients with type 2 diabetes

Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219 · see citing works

Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

Færch, K., Vistisen, D., Pacini, G., Torekov, S. S., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., et al. (2016) · Diabetes · doi:10.2337/db16-0240 · Cited by 217 · see citing works

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?

Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215 · see citing works

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Mannucci, E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., & Rotella, C. M. (2005) · Diabetologia · doi:10.1007/s00125-005-1749-8 · Cited by 206 · see citing works

Insulin Regulates Glucagon-Like Peptide-1 Secretion from the Enteroendocrine L Cell

Lim, G. E., Huang, G. J., Flora, N., LeRoith, D., Rhodes, C. J., & Brubaker, P. L. (2009) · Endocrinology · doi:10.1210/en.2008-0726 · Cited by 200 · see citing works

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197 · see citing works

Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism

Chai, W., Dong, Z., Wang, N., Wang, W., Tao, L., Cao, W., & Liu, Z. (2012) · Diabetes · doi:10.2337/db11-1073 · Cited by 194 · see citing works

Incretin hormones and type 2 diabetes

Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190 · see citing works

GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation

Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189 · see citing works

Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance

Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173 · see citing works

Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes

Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158 · see citing works

Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic Gluconeogenesis

Lee, Y.-S., Shin, S., Shigihara, T., Hahm, E., Liu, M.-J., Han, J., Yoon, J.-W., & Jun, H.-S. (2007) · Diabetes · doi:10.2337/db06-1182 · Cited by 158 · see citing works

Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice

Moriya, R., Shirakura, T., Ito, J., Mashiko, S., & Seo, T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00412.2009 · Cited by 156 · see citing works

The intestine as an endocrine organ and the role of gut hormones in metabolic regulation

Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144 · see citing works

The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications

Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146 · see citing works

Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus

Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140 · see citing works

Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets

Sloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143 · see citing works

Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review

Bodnaruc, A. M., Prud’homme, D., Blanchet, R., & Giroux, I. (2016) · Nutrition &amp; Metabolism · doi:10.1186/s12986-016-0153-3 · Cited by 139 · see citing works

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137 · see citing works

Pancreatic β-Cell Proliferation in Obesity

Linnemann, A. K., Baan, M., & Davis, D. B. (2014) · Advances in Nutrition · doi:10.3945/an.113.005488 · Cited by 132 · see citing works

Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes

Salehi, M., Aulinger, B., Prigeon, R. L., & D'Alessio, D. A. (2010) · Diabetes · doi:10.2337/db09-1253 · Cited by 124 · see citing works

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125 · see citing works

Incretins: their physiology and application in the treatment of diabetes mellitus

Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121 · see citing works

Rapid improvement in diabetes after gastric bypass surgery

Lingvay, I., Guth, E., Islam, A., & Livingston, E. (2013) · Diabetes Care · doi:10.2337/dc12-2316 · Cited by 116 · see citing works

Disordered control of intestinal sweet taste receptor expression and glucose absorption in type 2 diabetes

Young, R. L., Chia, B., Isaacs, N. J., Ma, J., Khoo, J., Wu, T., Horowitz, M., & Rayner, C. K. (2013) · Diabetes · doi:10.2337/db13-0581 · Cited by 111 · see citing works

Regulation of Islet Hormone Release and Gastric Emptying by Endogenous Glucagon-Like Peptide 1 after Glucose Ingestion

Salehi, M., Vahl, T. P., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2008-0605 · Cited by 108 · see citing works

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

Uccellatore, A., Genovese, S., Dicembrini, I., Mannucci, E., & Ceriello, A. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0127-x · Cited by 99 · see citing works

Emerging treatments for post-transplantation diabetes mellitus

Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90 · see citing works

Incretins in obesity and diabetes

Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93 · see citing works

Recent advances in clinical practice challenges and opportunities in the management of obesity

Acosta, A., Abu Dayyeh, B. K., Port, J. D., & Camilleri, M. (2014) · Gut · doi:10.1136/gutjnl-2013-306235 · Cited by 91 · see citing works

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85 · see citing works

What is GLP-1 really doing in obesity?

Hira, T., Pinyo, J., & Hara, H. (2020) · Trends in Endocrinology &amp; Metabolism · doi:10.1016/j.tem.2019.09.003 · Cited by 74 · see citing works

The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes

Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73 · see citing works

Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives

Ahrén, B. (2013) · Diabetes &amp; Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64 · see citing works

Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion

Holter, M. M., Saikia, M., & Cummings, B. P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.934775 · Cited by 63 · see citing works

GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance

Matikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H. (2014) · Diabetes Care · doi:10.2337/dc13-1283 · Cited by 63 · see citing works

Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review

Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62 · see citing works

Four weeks of near‐normalization of blood glucose has no effect on postprandial GLP‐1 and GIP secretion, but augments pancreatic B‐cell responsiveness to a meal in patients with Type 2 diabetes

Højberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56 · see citing works

Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects

Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50 · see citing works

Gut mechanisms linking intestinal sweet sensing to glycemic control

Kreuch, D., Keating, D. J., Wu, T., Horowitz, M., Rayner, C. K., & Young, R. L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00741 · Cited by 40 · see citing works

Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline

Irwin, N., Flatt, P. R., Patterson, S., & Green, B. D. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.11.022 · Cited by 38 · see citing works

Effect of low- and high-glycemic load on circulating incretins in a randomized clinical trial

Runchey, S. S., Valsta, L. M., Schwarz, Y., Wang, C., Song, X., Lampe, J. W., & Neuhouser, M. L. (2013) · Metabolism · doi:10.1016/j.metabol.2012.07.006 · Cited by 30 · see citing works

Management of type 2 diabetes: the role of incretin mimetics

Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29 · see citing works

A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects

Ikushima, I., Jensen, L., Flint, A., Nishida, T., Zacho, J., & Irie, S. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0677-1 · Cited by 28 · see citing works

Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies

Stonehouse, A., Walsh, B., & Cuddihy, R. (2011) · Diabetes Technology &amp; Therapeutics · doi:10.1089/dia.2011.0076 · Cited by 26 · see citing works

Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women

Seon, M. J., Hwang, S. Y., Son, Y., Song, J., & Kim, O. Y. (2021) · Nutrients · doi:10.3390/nu13030865 · Cited by 21 · see citing works

Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women

Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15 · see citing works

Pharmacologic inhibition of somatostatin receptor 2 to restore glucagon counterregulation in diabetes

Hoffman, E. G., D’Souza, N. C., Liggins, R. T., & Riddell, M. C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1295639 · Cited by 13 · see citing works

Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis

Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12 · see citing works

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

Nauck, M. A., Bartels, E., Ørskov, C., Ebert, R., & Creutzfeldt, W. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.4.8473405 · Cited by 505 · see citing works

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

Deacon, C. F., Wamberg, S., Bie, P., Hughes, T., & Holst, J. J. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720355 · Cited by 146 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Novel extrapancreatic effects of incretin

Yamada, Y., Tsukiyama, K., Sato, T. K., Shimizu, T., Fujita, H., & Narita, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12495 · Cited by 25 · see citing works

Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity

Gaffey, R. H., Takyi, A. K., & Shukla, A. P. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2377319 · Cited by 7 · see citing works